SCHEDULE 13G: Adage Capital Management Discloses 8.64% Stake in Praxis Precision Medicines
Beneficial Ownership Report
Adage Capital Management, L.P., along with Robert Atchinson and Phillip Gross, has reported a beneficial ownership of 8.64% in Praxis Precision Medicines, Inc.'s common stock as of March 31, 2025.
Summary
- Adage Capital Management, L.P., Robert Atchinson, and Phillip Gross collectively reported beneficial ownership of 1,742,758 shares of Praxis Precision Medicines, Inc. common stock.
- This ownership represents 8.64% of the company's outstanding common stock.
- The percentage is calculated based on an aggregate of 20,163,250 shares of Common Stock outstanding as of February 26, 2025, as reported in the company's Annual Report on Form 10-K for the fiscal year ended December 31, 2024.
- The Reporting Persons hold shared voting power and shared dispositive power over all 1,742,758 shares.
- The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Praxis Precision Medicines, Inc.
Sentiment
Score: 5
Explanation: A Schedule 13G filing is a factual disclosure of beneficial ownership and does not inherently convey positive or negative sentiment regarding the company's performance or outlook. The sentiment is neutral as it simply reports a stake.
Positives
- Significant institutional investment by Adage Capital Management, a notable investment firm, which can signal confidence in Praxis Precision Medicines, Inc.
- The filing indicates the shares were acquired in the ordinary course of business, suggesting a long-term investment perspective rather than an activist stance.
Future Outlook
NA
Industry Context
This filing indicates a significant institutional investor's position in a biotechnology/pharmaceutical company, which is a common occurrence for investment firms specializing in life sciences. It does not provide broader industry trends or specific market analysis.
Stakeholder Impact
- Shareholders: Increased institutional ownership by a reputable firm like Adage Capital Management could be viewed positively, potentially signaling confidence and attracting further investor interest.
Key Dates
| Date | Description |
|---|---|
| 02/26/2025 | Date as of which 20,163,250 shares of Common Stock were reported outstanding in the company's 10-K. |
| 02/28/2025 | Date Praxis Precision Medicines, Inc. filed its Annual Report on Form 10-K for the fiscal year ended December 31, 2024. |
| 03/31/2025 | Date of event which requires the filing of this Schedule 13G statement. |
| 05/12/2025 | Filing date of the Schedule 13G statement. |
Keywords
Praxis Precision Medicines, Adage Capital Management, SEC Filing, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investment, Biotechnology, Pharmaceuticals
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.